Contamination, both particulate and microbial, remains a leading cause of FDA recalls and poses serious risks to patient safety. To address these challenges, the European Medicines Agency (EMA) has updated Annex 1 of the Good Manufacturing Practices (GMP) guidelines, mandating stricter controls for pharmaceutical manufacturers and their suppliers.
Our experts will break down the revised EMA GMP Annex 1 guidelines, examining their impact on pharmaceutical operations and highlighting the critical role of sterile primary packaging suppliers in achieving compliance.
This webinar will provide a clear understanding of the EMA Annex 1 revisions and their impact on pharmaceutical operations. Discover practical strategies for contamination control, including sterility assurance for primary packaging components, and gain insights into how Aptar Pharma’s innovative solutions can support compliance with the updated guidelines.
<span>By ticking this box, you are accepting <a href=”https://aptar.com/general-terms-and-conditions-of-use/” style=”color:white; text-decoration: underline;” target=”_blank”>Aptar’s Privacy Policy and General Terms and Conditions</a> and consenting to have your information shared, for marketing purposes, possibly outside of the European Union.</span>
